We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
How COVID-19 will change the management of other respiratory viral infections.
- Authors
Arabi, Yaseen M.; Derde, Lennie P. G.; Timsit, Jean-François
- Abstract
Except for RCTs showing a possible benefit of early remdesivir in hospitalized patients with COVID-19 and early inhaled interferon-beta in patients with mild COVID-19, COVID-19 antiviral therapies have been disappointing [[2]]. The divergent result in less severely ill patients, who benefit from therapeutic anticoagulation, shows that differential treatment effects occur for patients at different timepoints during their course of disease, underpinning the need for research in the most critically ill patients as a separate group [[12]]. HFNO: high-flow nasal oxygen, NIV: noninvasive ventilation (NIV), ECMO: extracorporeal membrane oxygenation, RCT: randomized controlled trial Antiviral therapy Treatment of viral infections with agents with antiviral properties seems intuitive, but COVID-19 has proven that the issue is more complicated.
- Subjects
RESPIRATORY infections; VIRUS diseases; COVID-19; MEDICAL research; MIDDLE East respiratory syndrome
- Publication
Intensive Care Medicine, 2021, Vol 47, Issue 10, p1148
- ISSN
0342-4642
- Publication type
Article
- DOI
10.1007/s00134-021-06491-2